Comments
Shares of Aurobindo Pharma surged 3.64 per cent to Rs 1,065.90 on the NSE after the company informed the exchanges that Aurobindo Pharma USA Inc (Aurobindo Pharma Ltd's 100 per cent subsidiary) has emerged as the highest and best bidder to acquire Natrol Inc for $132.5 million (about Rs 800 crore).
Natrol manufactures and sells nutritional supplements in the US and other international markets.
The deal is pending final approval by the United States Bankruptcy Court for the District of Delaware, Aurobindo said in a statement.
The company beieves that Natrol is an excellent strategic fit and provides the right platform for creating a fully-integrated OTC platform in the US and other international markets.
Barclays provided financial advice to Aurobindo on the deal, while Sullivan & Cromwell LLP was the company's legal counsel.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.